Susceptibility and Protective Immunity to Noroviruses
Susceptibility and Protective Immunity to Noroviruses
批准号:
7639960
负责人:
Ralph S Baric
金额:
$66.07万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2014-03-31
关键词:
AccountingAcuteAddressAllelesAnimal ModelAntibodiesAntigenic VariationAntigensB-Lymphocyte EpitopesBacterial GastroenteritisBindingBinding SitesBiochemistryCapsidCapsid ProteinsCarbohydratesCessation of lifeChargeChildCommunitiesCrystallographyDataDeceptive ImprintingDeveloped CountriesDeveloping CountriesDisease OutbreaksElderlyEpidemicEpitopesEvolutionExposure toFamily suidaeFoodGastroenteritisGenesGenotypeGnotobioticGrantHerd ImmunityHospitalizationHumanHydrogen BondingImmuneImmune responseImmunityImmunologic SurveillanceInfantInfectionIngestionLigand BindingMalnutritionMapsMeasuresMediatingModelingMolecularMolecular StructureMonoclonal AntibodiesMusMutagenesisMutationNorovirusNorwalk virusOpen Reading FramesPathogenesisPatternPeripheral Blood Mononuclear CellPersonsPredispositionPropertyProphylactic treatmentPublic HealthRNA VirusesReagentRecombinant DNARetirementSiteStomachStructureSurfaceT-LymphocyteTestingTimeTissuesTrefoil MotifVaccinatedVaccinesVariantViralVirusVirus DiseasesVirus-like particleWateraerosolizedantigen bindingbaseflufoodbornehuman monoclonal antibodiesimmune functionimmunogenicityin vivomortalitypathogenpreventpublic health relevancereceptorreceptor bindingresponsetherapeutic vaccinetissue tropismvaccination strategyvolunteer
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Noroviruses are the most important cause of food-borne gastroenteritis worldwide and cause ~85-96% of selected outbreaks of acute non-bacterial gastroenteritis in the US. Heralded as the "stomach flu", retirement community outbreaks are pervasive and can result in 1-2% mortality rates in the elderly. Based on capsid sequences norovirus are divided into 5 genogroups. Genogroup I (GI) and II (GII) account for almost all human infections. Each genogroup is further divided into genotypes. The GII.4 genotype is the causative agent of 70-80% of all norovirus outbreaks worldwide. The norovirus major capsid protein forms an icosohedral shell, contains major antigenic determinants and interacts with histoblood group antigen (HBGA) carbohydrates, putative receptors for entry. This study investigates the molecular mechanisms governing norovirus capsid evolution, structure and HBGA recognition as a function of immune driven antigenic drift and deceptive imprinting. We identify the mechanisms by which replacement strains evolve over time, recognize new HBGA carbohydrate binding targets, and escape from highly penetrent host susceptibility alleles and protective herd immunity. While defining the relationships between mutation, antigenic variation, immunogenicity, deceptive imprinting, structure and HGBA binding, our interdisciplinary team simultaneously develops a robust GII.4 challenge model in swine and characterizes human monoclonal antibodies (mAb) to GI and GII strains, providing key reagents for advancing the field. PUBLIC HEALTH RELEVANCE: for Noro grant Noroviruses are the most important cause of food-borne gastroenteritis worldwide and cause ~85-96% of selected outbreaks of acute non-bacterial gastroenteritis in the US. Noroviruses are transmitted via ingestion of fecally contaminated food and water, exposure to contaminated surfaces, aerosolized vomitus and direct person-to-person contact. The tremendous public health significance of norovirus is evidenced by the estimated ~23,000,000 infections, 50,000 hospitalizations, and 310 fatal cases in the US. In developing nations, repeat infection likely contribute to malnutrition in infants and young children and may result in death. This proposal tests the hypothesis that Norovirus strains evolve over time to use varying cellular receptors and avoid host immune surveillance. If this model is correct, then long-term strain specific protective immunity and immune prophylaxis can be formulated to protect against contemporary strain infections providing a much needed vaccination strategy against this important human pathogen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core A: Administrative Core
-
批准号:10513680
-
项目类别:
-
资助金额:$920.22万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Development of direct-acting flavivirus inhibitors
-
批准号:10513687
-
项目类别:
-
资助金额:$395.75万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Core B: Virology Core
-
批准号:10425027
-
项目类别:
-
资助金额:$215.31万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Research Project 1: Coronavirus antiviral lead development and combination testing
-
批准号:10513684
-
项目类别:
-
资助金额:$508.76万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
RAPIDLY EMERGING ANTIVIRAL DRUG DEVELOPMENT INITIATIVE- AViDD CENTER (READDI-AC)
-
批准号:10513679
-
项目类别:
-
资助金额:$6548.32万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Development of Antivirals against Filovirus Replication
-
批准号:10513686
-
项目类别:
-
资助金额:$379.6万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Systems Immunogenetics of Emerging Coronavirus Infections in the Collaborative Cross
-
批准号:10180497
-
项目类别:
-
资助金额:$10.32万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
North Carolina Seronet Center for Excellence
-
批准号:10855051
-
项目类别:
-
资助金额:$295.01万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Project 1: Serological Correlates of SARS CoV2 Immunity and Disease
-
批准号:10688377
-
项目类别:
-
资助金额:$35.01万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Human antibody-based countermeasures against the Coronavirus SARS-CoV-2
-
批准号:10264078
-
项目类别:
-
资助金额:$120.62万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Systems Immunogenetics of Biodefense and Emerging Pathogens in the Collaborative Cross
-
批准号:10265701
-
项目类别:
-
资助金额:$9.12万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV
-
批准号:10189984
-
项目类别:
-
资助金额:$45.81万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
North Carolina Seronet Center for Excellence
-
批准号:10222240
-
项目类别:
-
资助金额:$397.46万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Core A: Administrative Core
-
批准号:10222241
-
项目类别:
-
资助金额:$51.76万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Antibody Landscape following Human Norovirus Infection and Vaccination
-
批准号:10350601
-
项目类别:
-
资助金额:$73.72万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative Cross
-
批准号:10271310
-
项目类别:
-
资助金额:$76.61万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2
-
批准号:10684696
-
项目类别:
-
资助金额:$119.78万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Systems Immunogenetics of Biodefense and Emerging Pathogens in the Collaborative Cross
-
批准号:10265699
-
项目类别:
-
资助金额:$30.95万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative Cross
-
批准号:10686223
-
项目类别:
-
资助金额:$76.61万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Respiratory Virus Vaccine and Adjuvant Exploration - Equipment Supplement
-
批准号:10242434
-
项目类别:
-
资助金额:$108.85万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
海外基金